Choate投资顾问出售了Edwards Lifesciences的股份,但公司打破了收益预期。 Choate Investment Advisors sold shares in Edwards Lifesciences, but the company beat earnings expectations.

Choate投资顾问通过出售20 624股,减少了其在医疗技术公司Edwards LifeSciences的股份,目前拥有129 357股,价值957万美元。 Choate Investment Advisors reduced its holdings in medical tech company Edwards Lifesciences by selling 20,624 shares, now owning 129,357 shares worth $9.57 million. Edwards LifeSciences比预期的收入要高,每股0.59美元,而预测为0.55美元。 Edwards Lifesciences beat earnings expectations, reporting $0.59 per share compared to forecasts of $0.55. 尽管体制性出售,分析家预测该公司当年将报告2,45 EPS。 Despite institutional sell-offs, analysts predict the company will report 2.45 EPS for the year. Edwards生命科学专门研究心脏病和关键护理产品。 Edwards Lifesciences specializes in heart disease and critical care products.